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Background: Previous studies have indicated that survivors of childhood acute lymphoblastic leukemia (ALL) have
an increased morbidity measured in terms of health care utilization. However, earlier studies have several potentially
important limitations. To overcome some of these, we investigated hospital contact rates, and predictors thereof,
among 5-year survivors of ALL in a population-based setting, and compared them to a control cohort regarding
outcome measures from a comprehensive nation-wide health register.
Methods: All individuals diagnosed with ALL before the age of 18 in Southern Sweden during 1970–1999 and alive
January 2007 (n = 213; male = 107) were identified through the Swedish Cancer Register. Each subject was matched
to fifty controls, identified in the Swedish Population Register. All study subjects were linked to the National
Hospital Register and detailed information was obtained on all hospital contacts (hospital admissions and
outpatients visits) starting five years after cancer diagnosis, and the corresponding date for the controls, until 2009.
Results: The median follow-up among the 5-year survivors of ALL was 16 years (range 5–33), accruing a total of
3,527 person-years. Of the 213 5-year survivors, 105 (49.3%) had at least one hospital contact compared to 3,634
(34.1%) of the controls (p < 0.001). Survivors had more hospital contacts (3 [1–6] vs. 2 [1–4] contacts, p < 0.001) and
more total days in hospital (6 [2–18] vs. 3 [1–7] days, p < 0.001) than the controls during the study period. Logistic
regression analysis showed that survivors treated with cranial irradiation and/or total body irradiation (45% and 7%,
respectively) had an increased risk of at least one hospital contact (OR 2.3, 95%CI; 1.5–3.6 and OR 11.0, 95%CI;
3.2–50.7, respectively), while there was no significant difference between the non-irradiated survivors and controls.
Conclusions: We show that irradiated survivors of childhood ALL have an increased morbidity measured in terms
of hospital contacts, in comparison to non-irradiated survivors and controls, while non-irradiated survivors have not.
These findings are encouraging regarding the future morbidity of children currently treated for ALL, as radiotherapy
is necessary only for a minority of these.
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Survival rates for children with cancer have improved
dramatically during the past four decades. Acute
lymphoblastic leukemia (ALL), the most common child-
hood malignancy, accounts for approximately 25% of all
pediatric cancers. Today, 85% of children with ALL
treated in the Nordic countries survive more than five
years [1].
As the population of adult survivors of childhood cancer
grows, late complications, arising primarily from the can-
cer treatment, are becoming increasingly evident. These
late effects include cardiovascular, endocrine, pulmonary,
neurological and cognitive complications, as well as effects
on fertility, musculoskeletal structures, hearing and vision.
There is also an increased risk of secondary malignancies
and premature death [2-10]. More than two thirds of
survivors may develop a chronic condition as a long-
term complication, and this fraction seems to increase
with longer follow-up [11-13].
Health care utilization can be used as an indirect meas-
ure of overall morbidity. Two studies in British Columbia,
Canada, comparing hospitalizations in a cohort of child-
hood cancer survivors with population controls, showed
that survivors were hospitalized to a greater extent than
the controls [14,15]. In the first study, where leukemia
survivors were analyzed separately, an increased relative
risk of hospitalization was seen, irrespective of treat-
ment regime [15]. Self-reported hospitalization was
found to be higher among survivors of leukemia in the
North American Childhood Cancer Survivor Study
(CCSS)[16]. In this article, the authors call for further
research to fully describe health care utilization among
childhood cancer survivors [16].
Health care utilization, as a measure of morbidity, is
affected by the representativeness of the study group
and the control group, as well as the collection of out-
come data. Previous studies mostly report on health care
utilization after all types of childhood cancer and not
specifically on leukemia survivors. Other studies are lim-
ited by high rates of loss to follow-up, possible recall
bias in questionnaire studies, and lack of appropriate
control groups.
In-depth knowledge of the morbidity of childhood
cancer survivors is essential for the further development
of treatment protocols, improved prevention strategies,
patient counseling and follow-up care. To clarify the
extent and causes of hospital contacts among the large
group of survivors of ALL in childhood, we conducted
this population-based, retrospective study. The present
study has the strength of including data from comprehen-
sive nationwide registers, and a large matched control
group from the general population, thereby avoiding some
of the shortcomings of previous studies. We investigated
the number of hospital contacts, the length of hospitalstays and the diagnoses of the hospital contacts among
ALL survivors and compared these to those of the control
cohort. In addition, we investigated potential risk factors
for morbidity, including relapse and treatment with cranial
and total body irradiation, in order to facilitate specific
health care planning for subgroups of ALL survivors in




A database (BORISS, Childhood Cancer Register of
Southern Sweden) has been established at the Department
of Pediatric Oncology and Hematology, Skåne University
Hospital, Lund, Sweden [17]. This database contains infor-
mation on all individuals living in the Southern region of
Sweden at the time of diagnosis (current population 1.7
million) who were diagnosed with cancer before the age of
18, during the period 1970–1999. BORISS was established
in collaboration with the Swedish Cancer Register, which
covers virtually all cases of cancer in Sweden since 1958
[18]. Information on diagnosis and treatment, collected
from the medical records of 1,617 children diagnosed with
cancer, are included in the BORISS database. In January
2007, 1,106 of these individuals were still alive, 213 (107
men, 106 women) of whom were survivors of ALL.
None of the 213 survivors of ALL had Down’s syn-
drome, as confirmed by medical records.
Control cohort
A randomly sampled control cohort of 10,650 individuals
(50 controls per survivor) was identified in the Population
Register of Sweden (Statistics Sweden), which contains
basic demographic information on the entire Swedish
population. The controls were matched for gender, year of
birth and county of residence of the year of diagnosis of
the corresponding patient. In Sweden, all individuals are
assigned a unique personal identification number, which
allows accurate linkage of information between various
registers.
Outcome variables
In the Swedish National Hospital Register, we identified
all hospital admissions and outpatient visits (referred to
as hospital contacts), as well as information on up to 20
discharge diagnoses for all hospital contacts from 5 years
after the diagnosis of ALL, or the corresponding date for
the controls, until the end of follow-up on December 31,
2009, for both cohorts. In the event of a relapse, hospital
contacts within the first five years after diagnosis of relapse
were excluded. The Swedish National Hospital Register
includes information on hospital admissions in various
parts of the country since 1964, and for the entire coun-
try since 1987; in addition, information on outpatient
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since 2001 [19]. Registration is mandatory. To reflect
clinically meaningful entities of low, medium and high
severity, the total number of hospital contacts was di-
vided into three groups: 0, 1–2 or at least 3, and the
sum of the number of days in hospital into four groups:
0, 1–7 days, 8–30 days or more than 30 days.
Discharge diagnoses during the study period are coded
in the National Hospital Register according to three differ-
ent versions of International Classification of Diseases
(ICD); i.e., ICD-8 (1969–1986), ICD-9 (1987–1996) and
ICD-10 (1997 and onwards). Hospital outpatient visits
were included starting 2001. Discharge diagnoses related
to pregnancy, delivery and perinatal period were excluded
(ICD-10: O00–O99, ICD-9: 630–676, ICD-8: 630–678).
If the main discharge diagnosis recorded in the National
Hospital Register was ALL (ICD-8: 204.0, 204.9, 207.0,
ICD-9: 204, 207, 208, ICD-10: C910, C91.9, C950, C95.7,
C95.9), the secondary diagnosis was chosen. If all dis-
charge diagnoses (including the main diagnosis) registered
for a specific hospital contact were ALL, it was excluded
from the analysis since it most likely represented a routine
follow-up after ALL, according to the standard in Sweden
with follow-up of childhood cancer survivors at hospitals
until at least the age of 18 years. On all other occasions,
only the main discharge diagnosis was included in the
analyses.
The main diagnostic groups were selected according
to the ICD, except the group of infectious diseases,
which in this study includes both the original main
group entitled “Certain infectious and parasitic diseases”
and diagnostic codes from other main groups including
site-specific infections (meningitis, otitis, acute infections
in the upper airways, influenza, pneumonia, other acute
infections in the lower airways and infections of the
airways).
Socio-economic data was collected from registers main-
tained by Statistics Sweden. The parents of the subjects
were identified in the Swedish Multigenerational Register,
which is part of the Population Register.
Exposure variables
The information on cancer treatment collected from med-
ical records includes type and amount of radiotherapy
(continuous variable). The three ALL survivors who in
addition to chemotherapy received both cranial irradiation
and total body irradiation, were classified together with
survivors treated with total body irradiation and chemo-
therapy. Information on possible relapse was collected
from medical records. Age at diagnosis of ALL was di-
vided into three groups; <5, 5–9 and ≥10 years of age.
The highest level of education of the father and mother,
respectively, was divided into five groups; less than
9 years, completed secondary school, high school,college/university and graduate school, respectively.
The country of birth of the father was divided into three
groups; Sweden, other Nordic country and other coun-
try. For the analyses of the influence of parents’ income,
the annual income of the parent with the highest income
at the year of diagnosis of the study subject, or the corre-
sponding year of the control, was chosen.
The study was approved by the Regional Ethics Review
Board, Lund University (official records numbers; 113/
2007, 2010/98, 2010/504).
Statistical analyses
Comparisons of the number of hospital contacts, the
number of days in hospital and diagnoses of hospital
contacts between survivors and controls were performed
using the chi-squared test. The numbers of hospital con-
tacts and days in hospital were also analyzed using the
Mann–Whitney test. Comparisons regarding diagnosis
of hospital contacts, as well as the socio-economic vari-
ables, between survivors and controls were performed
using the chi-squared test. In these analyses p-values
of <0.05 were considered significant. Continuous data
are expressed as median and interquartile range unless
stated otherwise.
The influence of treatment modalities and relapse on
the risk of having at least one hospital contact was ana-
lyzed using multilevel logistic regression with each ALL
survivor constituting a cluster together with its matched
controls. The influence of treatment modalities and
relapse on the number of hospital contacts and days in
hospital was analyzed using ordinal logistic regression.
No further adjustments were made. The impact of cranial
irradiation dose on hospital contacts was investigated
using logistic regression, adjusted for time period of
diagnosis (decennium), gender, age at diagnosis, parent’s
income, country of birth of father and highest level of
education of the parents.
The influence of gender and age at diagnosis on the
risk of having at least one hospital contact was analyzed
using multilevel logistic regression, while the influence
on the number of hospital contacts and days in hospital
was analyzed using ordinal logistic regression. Interaction
terms between these outcome variables and survivors were
used and backward elimination of unnecessary factors
according to Bayesian Information Criterion was used.
The statistical analyses were performed using the soft-
ware package SPSS Statistics 16.0 and R version 3.0.1.
Results
Clinical characteristics
The clinical characteristics of the 213 survivors of ALL
are presented in Table 1. Median age at diagnosis was
4 years (range 0–17) and 52% of the survivors were diag-
nosed with ALL before the age of five. The median
Table 1 Clinical characteristics of 5-year survivors of acute lymphoblastic leukemia
ALL survivors Chemotherapy only CRT TBI
n = 213 % n = 104 % n = 95 % n = 14 %
Age at diagnosis
<5 yrs 111 52.1 61 58.7 45 47.4 5 35.7
5-9 yrs 71 33.3 34 32.7 33 34.7 4 28.6
10-17 yrs 31 14.6 9 8.7 17 17.9 5 35.7
Period of diagnosis
1970-1979 42 19.7 3 2.9 39 41.1 0 0
1980-1989 78 36.6 39 37.5 32 33.7 7 50.0
1990-1999 93 43.7 62 59.6 24 25.3 7 50.0
Age at end of follow-up
10-19 yrs 54 25.4 46 44.2 6 6.3 2 14.3
20-29 yrs 71 33.3 39 37.5 26 27.4 6 42.9
30-39 yrs 73 34.3 15 14.4 53 55.8 5 35.7
>40 yrs 15 7.6 4 3.8 10 10.5 1 7.1
Relapse 24 11.3 2 1.9 11 11.6 11 78.6
Stem cell transplantation 14 6.6 0 0 0 0 14 100.0
Cranial irradiation
12-15 Gy 2 0.9 2 2.1 0 0
18 Gy 28 13.1 28 28.4 1 7.1
20-23 Gy 6 2.8 6 6.3 0 0
24-30 Gy 62 29.1 60 63.2 2 14.3
Total body irradiation
8-12 Gy 14 6.6 14 100.0
Abbreviations: ALL acute lymphoblastic leukemia, CRT received cranial irradiation in addition to chemotherapy, TBI received total body irradiation in addition to
chemotherapy, including three cases who, in addition, received cranial irradiation.
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(range 5–33) accruing a total of 3,527 person-years of
follow-up. The control cohort constituted 10,650 individ-
uals, monitored for a total of 176,750 person-years.
The socio-economic characteristics of the ALL survivors
and controls are presented in Table 2.
Rate of hospital contacts
Of the 213 5-year survivors of ALL, 105 (49.3%) were
admitted to hospital at least once during the study
period starting five years after ALL diagnosis and ending
in 2009, as were 3,634 (34.1%) of the controls (p < 0.001).
In addition, among individuals with at least one admission,
ALL survivors had more hospital contacts (in total 3 [1–6]
vs. 2 [1–4], p < 0.001), and spent more days in hospital (in
total 6 [2–18] vs. 3 [1–7] days, p < 0.001) than the controls
during the study period (Table 3).
Diagnoses of hospital contact
Among those who were hospitalized at least once, diag-
noses of infectious disease, benign neoplasms, diseases
of the blood, endocrine diseases, diseases of the nervous
system, eye, ear, circulatory system, and the skin were
significantly more frequent in survivors than controls, ascan be seen in Table 4. In contrast, the diagnosis of pul-
monary disease was significantly more frequent among
controls.Treatment as a risk factor for hospital contacts
As can be seen from Table 1, 95 of the 213 survivors
underwent cranial irradiation in addition to chemother-
apy, and 14 underwent total body irradiation in addition
to chemotherapy (including three cases in whom cranial
radiation was given in addition to total body irradiation).
Multi-level logistic regression analysis showed that sur-
vivors treated with cranial irradiation and/or total body
irradiation, in addition to chemotherapy, had a signifi-
cantly increased risk of having at least one hospital con-
tact during the study period, compared to non-irradiated
survivors and controls (OR 2.3 and 11.0, respectively)
(Table 5). Among the subjects who had at least one hos-
pital contact, survivors treated with cranial irradiation
and/or total body irradiation had significantly more hos-
pital contacts, with 3.9 and 4.8 times higher risks, than
the non-irradiated survivors and controls (Table 5). Like-
wise, the number of days in hospital was increased only
among those treated with cranial irradiation and/or total
Table 2 Socio-economic characteristics concerning 5-year survivors of acute lymphoblastic leukemia and controls
ALL survivors Controls
p-value
n = 213 % n = 10,650 %
Male 107 50.2 5350 50.2
1.0
Female 106 49.8 5300 49.8
Born
1965-1969 15 7.0 750 7.0
1.0
1970-1979 73 34.3 3650 34.2
1980-1989 71 33.3 3550 33.3
1990-1999 54 25.4 2700 25.4
Highest level of education of father
Less than 9 years 30 14.1 1545 14.5
0.943
Completed secondary school (9 years) 37 17.3 1636 15.3
Graduated from high school 77 36.1 3857 36.2
College/University 46 21.6 2227 20.9
Graduate school 4 1.9 123 1.2
Missing 19 8.9 1262 11.8
Highest level of education of mother
Less than 9 years 15 7.0 1021 9.6
0.771
Completed secondary school (9 years) 45 21.1 1845 17.3
Graduated from high school 87 40.8 4340 40.8
College/University 52 24.4 2523 23.7
Graduate school 0 0 19 0.2
Missing 14 6.6 902 8.5
Country of birth of father
Sweden 183 85.9 9055 85.0
0.324Nordic country, except Sweden 10 4.7 315 3.0
Other than Nordic country 19 8.9 1058 9.9
Missing 1 0.5 222 2.1
Table 3 Distribution (percentage) among 5-year survivors of acute lymphoblastic leukemia and controls by number of
hospital contacts and days in hospital
Chemotherapy only CRT TBI Relapse ALL survivors Controls
p-value2
n = 104 n = 95 n = 14 n = 24 n = 213 n = 10,650
At least one hospital contact1 35.9 59.4 78.6 66.7 49.3 34.1 < 0.001
Total number of hospital contacts
1–2 25.2 24.0 50.0 33.3 28.2 26.6
< 0.001
≥3 10.7 35.4 28.6 33.3 21.1 7.6
Total number of days in hospital
1–7 days 24.3 26.0 50.0 25.0 26.8 25.7
< 0.0018–30 days 7.8 18.8 14.3 12.5 13.1 5.9
> 30 days 3.9 14.6 14.3 29.2 9.4 2.5
1Hospital contacts from 5 years after the diagnosis of ALL, or the corresponding date for the controls, until the end of follow-up. In the case of a relapse, hospital
contacts within the first five yeas after diagnosis of relapse were excluded, 2p-value for comparison between all survivors and controls. Abbreviations: CRT received
cranial irradiation in addition to chemotherapy, TBI received total body irradiation in addition to chemotherapy, including three cases who, in addition, received
cranial irradiation.
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Table 4 Main diagnosis of hospital contact of survivors of acute lymphoblastic leukemia and controls




n % n %
Certain infectious and parasitic diseases (000–136, 001–139, A00-B99)1 20 9.4 475 4.5 0.002
Benign and in situ neoplasms and neoplasms of uncertain or unknown behavior (210–239, 210–239, D00-D48) 8 3.8 77 0.7 <0.001
Malignant neoplasm (140–209, 140–208, C00-C97) 1 0.5 3 0.0 NS
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
(280–289, 280–289, D50-D89)
11 5.2 120 1.1 <0.001
Endocrine, nutritional and metabolic diseases (240–279, 240–279, E00-E90) 15 7.0 197 1.8 <0.001
Mental and behavioral disorders (290–315, 290–319, F00-F99) 9 4.2 380 3.6 NS
Diseases of the nervous system (320–358, 320–359, G00-G99; infections excluded) 11 5.2 130 1.2 <0.001
Diseases of the eye and adnexa (360–379, 360–379, H00-H59; infections excluded) 6 2.8 123 1.2 0.041
Diseases of the ear and mastoid process (380–389, 380–389, H60-H95; infections excluded) 6 2.8 128 1.2 0.048
Diseases of the circulatory system (390–458, 390–459, I00-I99; infections excluded) 7 3.3 152 1.4 0.037
Diseases of the respiratory system (460–519, 460–519, J00-J99; infections excluded) 2 0.9 434 4.1 0.013
Diseases of the digestive system (520–577, 520–579, K00-K93; infections excluded) 14 6.6 721 6.8 NS
Diseases of the skin and subcutaneous tissue (680–709, 680–709, L00-L99; infections excluded) 13 6.1 252 2.4 0.002
Diseases of the musculoskeletal system and connective tissue (710–738, 710–739, M00-M99; infections excluded) 5 2.3 335 3.1 NS
Diseases of the genitourinary system (580–629, 580–629, N00-N99; infections excluded) 18 8.5 586 5.5 NS
Injury, poisoning and certain other consequences of external causes (800–999, 800–999, S00-T98) 23 10.8 1,268 11.9 NS
1Including diagnostic codes from other main groups including site-specific infections (meningitis, otitis, acute infections in the upper airways, influenza,
pneumonia, other acute infections in the lower airways, and infections of the airways, i.e. main groups VI-XIV. 2Chi2-test comparing survivors and controls.
Table 5 Odds ratios for hospital contacts of survivors of
acute lymphoblastic leukemia compared to controls,
according to treatment modalities
OR 95% CI p-value
At least one hospital contact1
Controls 1
Chemotherapy only 1.4 0.9–2.2 0.10
Cranial irradiation2 2.3 1.5–3.6 < 0.001
Total body irradiation3 11.0 3.2–50.7 < 0.001
Increased number of hospital contacts1
Controls 1
Chemotherapy only 1.1 0.8–1.7 0.53
Cranial irradiation2 3.9 2.6–5.9 < 0.001
Total body irradiation3 4.8 1.9–12.3 < 0.001
Increased number of days in hospital1
Controls 1
Chemotherapy only 1.2 0.8–1.7 0.43
Cranial irradiation2 3.7 2.5–5.5 < 0.001
Total body irradiation3 5.6 2.2–14.3 < 0.001
1Hospital contacts from 5 years after the diagnosis of ALL, or the
corresponding date for the controls, until the end of follow-up. In the case of
a relapse, hospital contacts within the first five yeas after diagnosis of relapse
were excluded. 2Treated with cranial irradiation in addition to chemotherapy.
3Treated with total body irradiation in addition to chemotherapy. OR = odds
ratio, CI = confidence interval.
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and controls (OR 3.7 and 5.6, respectively) (Table 5).
There was no significant difference between the non-
irradiated survivors and controls regarding the risk of
being hospitalized at least once, the number of days in
hospital or the number of hospital contacts (Table 5).
The amount of cranial irradiation influenced the risk of
hospital contacts. For every additional Gray of irradi-
ation administered to the head, the risk of having at least
one hospital contact increased by 5% (OR 1.05, 95% CI;
1.03–1.07).
Relapse did not alter the risk of hospital contacts,
number of days in hospital, or number of hospital con-
tacts when hospital contacts within the first five years
after diagnosis of relapse were excluded, but the power
for detecting a possible increase in risk is small due
to the low number of relapses in the present study
(Table 3).
Socio-demographic risk factors for hospital contacts
Females more frequently had at least one hospital con-
tact, and an increased number of hospital contacts and
days in hospital than males, but this gender difference
was the same among survivors and controls (Table 6).
Females had at least one hospital contact to a significantly
greater extent than males also when the subgroups of
non-irradiated and irradiated survivors were analyzed
and the interaction term between gender and treatment
modality was non significant (data not shown). Age at
Table 6 Odds ratios for hospital contacts by clinical characteristics
At least one hospital
contact
Increased number of hospital
contacts
Increased number of days in
hospital
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Study cohorts
Controls reference
ALL survivors 2.5 1.5–4.3 <0.001 2.7 1.6–4.3 <0.001 3.0 1.8–4.8 <0.001
Gender
Male reference
Female 1.3 1.1–1.7 0.007 1.3 1.3–1.5 <0.001 1.3 1.2–1.4 <0.001
Age at diagnosis
<5 yrs reference
5-9 yrs 1.0 0.8–1.3 0.94 1.0 0.9–1.1 0.72 1.0 0.9–1.1 0.73
10-17 yrs 0.9 0.6–1.2 0.40 0.9 0.8–1.0 0.02 0.9 0.8–1.0 0.03
Interaction terms
Case-Female 0.8 0.5–1.5 0.55 0.9 0.5–1.6 0.76 0.9 0.5–1.5 0.56
Case-age 5–9 yrs at diagnosis 0.8 0.4–1.6 0.62 0.8 0.5–1.5 0.52 0.8 0.4–1.4 0.34
Case-age 10–17 yrs at diagnosis 0.5 0.2–1.2 0.15 0.5 0.2–1.1 0.10 0.4 0.2–1.0 0.05
OR = odds ratio, CI = confidence interval.
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one hospital contact. However, among patients with at
least one hospital contact, age ≥ 10 years at diagnosis
was associated with fewer hospital contacts and days in
hospital (Table 6). The influence of socio-economic pa-
rameters did not differ between the group of survivors
and the control cohort (data not shown).
Discussion
In this population-based study, we found that irradiated
5-year survivors of ALL had more hospital contacts and
spent more days in hospital than both non-irradiated
survivors and matched population controls. This risk in-
creased with the amount of cranial irradiation received.
In contrast, non-irradiated survivors of ALL did not
have more hospital contacts, nor did they spend more
days in hospital, than controls. Among those who were
hospitalized at least once, a broad range of different
diagnoses of the hospital contacts were significantly
more frequent among ALL survivors than controls.
In the present study, comprising a follow-up from
1975 to 2009, 49% of survivors of ALL were hospitalized
at least once, which is similar to the proportion found in
leukemia survivors in British Columbia, Canada, where
40% had been hospitalized at least once (follow-up
1986–2000) [15]. Leukemia survivors included in the
CCSS had a standardized incidence ratio of self-reported
hospitalization of 1.4 (95%CI 1.3–1.4) compared with
the general U.S. population [16]. In the BCCSS, 7.1
percent of survivors of leukemia reported having been
hospitalized at least once during the observed year, a
1.4-fold risk compared with the general population(data from the National General Household Survey)
[20]. Thus, the findings of the present study are also
consistent with the results of the BCCSS and the CCSS.
The BCCSS has a long period of follow-up and is, like
the CCSS, a large study. However, both these studies
rely on self-reported outcome measures. Furthermore,
the CCSS includes patients only treated at the collaborat-
ing hospitals, while the present study is distinguished by
being strictly population-based and includes outcome
measures that are based on comprehensive nationwide
registers. An additional strength of the present study is the
use of a large, matched control cohort from the general
population.
Our finding of a broad range of discharge diagnoses
causing hospital contacts among survivors is supported in
two comparable studies [15,16]. Clearly, the increased risk
of hospital contacts among survivors of ALL compared to
the controls is caused by many different diagnoses. One ex-
ception in our study is the finding of a smaller proportion
of hospital contacts for pulmonary diseases in the group of
ALL survivors than in the control cohort, which is in con-
trast to that of the two earlier studies. One may speculate
that the different frequencies of pulmonary diseases in sur-
vivors and controls could be due to differences in smoking
habits between cancer survivors and controls. This hypoth-
esis is supported by the CCSS study, where survivors were
found to smoke less than the general population [21]. Un-
fortunately, information on smoking was not available in
the current study. We also found that survivors did not
have hospital contacts to a greater extent for mental disor-
ders, injuries or poisoning than controls, which is in con-
trast to previously published results [15,16].
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result in an increased risk of a broad range of late com-
plications, and efforts to reduce radiotherapy in treat-
ment protocols without compromising survival rates
have been successful for ALL patients during the last
three decades [22,23]. Nevertheless, Bradley et al. could
not find a specific treatment modality to be a risk factor
for hospitalization when survivors of all childhood cancers
were grouped together [14]. When leukemia survivors
were analyzed separately by Lorenzi et al., an increased
risk of hospitalization was seen among survivors treated
with chemotherapy only, as well as among those treated
with both chemotherapy and cranial irradiation, compared
to the control group [15]. In contrast to both these stud-
ies, we found an increased risk of having hospital contacts
only in the subgroups of survivors whose treatment in-
cluded radiotherapy in addition to chemotherapy. All
three studies are population- and register-based, but the
follow-up period of our study is longer, and we included
survivors diagnosed with ALL as early as 1970, which may
in part explain the disparities.
The main finding of our study that there is no in-
creased risk of hospital contacts of non-irradiated survi-
vors of ALL is supported by the CCSS study where the
vast majority (92%) of the non-irradiated, non-relapsed
survivors did not report any severe chronic medical con-
dition [24]. On the basis of the results of the present
study, follow-up of ALL survivors should primarily focus
on developing preventive interventions, and enhancing
patient counseling and follow-up care of those whose
treatment included irradiation.
Our data show that, in both the survivor cohort and
the control cohort, females had an increased risk for at
least one hospital contact, more hospital contacts and
longer hospital stays than males, which is in agreement
with previous studies [15,16]. Moreover, we found that
age at diagnosis did not influence the risk of having at
least one hospital contact, but in the age group ≥ 10 years
at cancer diagnosis, fewer hospital contacts and shorter
hospital stays were seen. In the CCSS, young age at
diagnosis was found to be associated with an increase in
risk of hospitalization, while Lorenzi et al. showed that
age at diagnosis did not significantly influence later
hospitalization [15,16]. However, all types of childhood
cancer were included in the analyses of the impact of
gender and age at diagnosis in these two studies, making
direct comparisons with our study difficult. In accordance
with the study by Lorenzi et al., we found that the influ-
ence of socio-economic factors on hospital contacts did
not differ between ALL survivors and controls.
The limitations of the current study must be considered.
The Swedish National Hospital Register includes hospital-
based outpatient data only since 2001, and no data from
general practitioners are included, so the present studymainly captures conditions resulting in admission to
hospital. In addition, the Swedish Hospital Register has
national coverage only since 1987, which further re-
duces the number of hospital contacts included in the
study. However, most parts of Southern Sweden have
had complete coverage since 1970. The current study
was not powered to look at the influence of treatment
era on health care utilization. However, we did analyze
the impact of treatment modality, which in part could
be seen as a substitute for treatment era. Information
on emigration and death was not considered in the
follow-up of the control cohort, which could potentially
have led to the underestimation of the rate of hospital
contacts in this cohort. However, given the size of the
control cohort, this potential underestimation should
not be of any substantial significance.Conclusions
In conclusion, we have demonstrated that irradiated sur-
vivors of ALL have an increased morbidity expressed in
terms of hospital contacts, compared to non-irradiated
survivors and controls from the general population. In
contrast, non-irradiated survivors of ALL did not have
more frequent hospital contacts or more days in hospital
than the controls. A broad range of different diagnoses
of the hospital contacts were significantly more frequent
in the ALL survivor cohort than in the control cohort.
Survivors did, however, not have hospital contacts for
mental diseases, injuries or poisoning, to a greater extent
than the controls, and they had a lower frequency of
hospital contacts due to pulmonary disease. This strictly
population-based study, based on comprehensive nation-
wide registers including over 30 years of follow-up, is
encouraging regarding morbidity for patients currently
treated for ALL, as radiotherapy is considered necessary
in only a minority.
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